Signant Health, a US-based company involved in evidence generation for modern clinical trials, announced on Monday that it has named Paul Richmond as its new chief commercial officer (CCO).

Richmond is a life sciences leader with more than 20 years' experience working with biopharma, biotech, and contract research organisations (CROs). He has served at global Contract Research Organisation (CRO) PPD, where he most recently served as senior vice president, global head of commercial clinical research division. He has served in pivotal roles including vice president of biotech and business development positions at both PPD and its patient enrolment arm, Accelerated Enrollment Solutions.

Roger Smith, Signant's chief executive officer, said, 'Having a seasoned industry leader like Paul in the role of chief commercial officer is important not just for Signant, but also for our customer mix of large and small sponsors, and CROs as well. His vast, diverse expertise and deep understanding of the complexities of our industry make him exceptionally well-suited to guide our customers in selecting solutions that are best suited to their protocol, disease area, and evidence generation strategies. Paul fundamentally understands that our customers want solutions that consistently capture high-quality data required for in-trial decisions and regulatory submission. He will be a great partner for them, and we are fortunate to add his calibre to our leadership team.'